Literature DB >> 26415052

In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells.

Yusuke Yamamoto1, Gang Ning1, Brooke E Howitt2, Karishma Mehra2, Lingyan Wu3, Xia Wang1, Yue Hong1, Florian Kern3, Tay Seok Wei3, Ting Zhang3, Niranjan Nagarajan3, Debargha Basuli4, Suzy Torti4, Molly Brewer5, Mahesh Choolani6, Frank McKeon1,3,7,8,9, Christopher P Crum2, Wa Xian1,2,7,10,11.   

Abstract

High-grade serous cancer (HGSC) progresses to advanced stages without symptoms and the 5-year survival rate is a dismal 30%. Recent studies of ovaries and Fallopian tubes in patients with BRCA1 or BRCA2 mutations have documented a pre-metastatic intramucosal neoplasm that is found almost exclusively in the Fallopian tube, termed 'serous tubal intraepithelial carcinoma' or STIC. Moreover, other proliferations, termed p53 signatures, secretory cell outgrowths (SCOUTs), and lower-grade serous tubal intraepithelial neoplasms (STINs) fall short of STIC but share similar alterations in expression, in keeping with an underpinning of genomic disturbances involved in, or occurring in parallel with, serous carcinogenesis. To gain insight into the cellular origins of this unique tubal pathway to high-grade serous cancer, we cloned and both immortalized and transformed Fallopian tube stem cells (FTSCs). We demonstrated that pedigrees of FTSCs were capable of multipotent differentiation and that the tumours derived from transformed FTSCs shared the histological and molecular features of HGSC. We also demonstrated that altered expression of some biomarkers seen in transformed FTSCs and HGSCs (stathmin, EZH2, CXCR4, CXCL12, and FOXM1) could be seen as well in immortalized cells and their in vivo counterparts SCOUTs and STINs. Thus, a whole-genome transcriptome analysis comparing FTSCs, immortalized FTSCs, and transformed FTSCs showed a clear molecular progression sequence that is recapitulated by the spectrum of accumulated perturbations characterizing the range of proliferations seen in vivo. Biomarkers unique to STIC relative to normal tubal epithelium provide a basis for novel detection approaches to early HGSC, but must be viewed critically given their potential expression in lesser proliferations. Perturbations shared by both immortalized and transformed FTSCs may provide unique early targets for prevention strategies. Central to these efforts has been the ability to clone and perpetuate multipotent FTSCs.
Copyright © 2015 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  Fallopian tubes; cell culture; neoplasia; ovary

Mesh:

Substances:

Year:  2016        PMID: 26415052      PMCID: PMC4895925          DOI: 10.1002/path.4649

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  50 in total

Review 1.  Ovarian surface epithelium: biology, endocrinology, and pathology.

Authors:  N Auersperg; A S Wong; K C Choi; S K Kang; P C Leung
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Mucinous adenocarcinoma developed from human fallopian tube epithelial cells through defined genetic modifications.

Authors:  Weiwei Shan; Imelda Mercado-Uribe; Jing Zhang; Daniel Rosen; Shiwu Zhang; Jianjun Wei; Jinsong Liu
Journal:  Cell Cycle       Date:  2012-06-01       Impact factor: 4.534

Review 3.  FOXM1, a typical proliferation-associated transcription factor.

Authors:  Inken Wierstra; Jürgen Alves
Journal:  Biol Chem       Date:  2007-12       Impact factor: 3.915

4.  Distal airway stem cells yield alveoli in vitro and during lung regeneration following H1N1 influenza infection.

Authors:  Pooja A Kumar; Yuanyu Hu; Yusuke Yamamoto; Neo Boon Hoe; Tay Seok Wei; Dakai Mu; Yan Sun; Lim Siew Joo; Rania Dagher; Elisabeth M Zielonka; De Yun Wang; Bing Lim; Vincent T Chow; Christopher P Crum; Wa Xian; Frank McKeon
Journal:  Cell       Date:  2011-10-28       Impact factor: 41.582

5.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).

Authors:  Subhash C Chauhan; Ajay P Singh; Fernanda Ruiz; Sonny L Johansson; Maneesh Jain; Lynette M Smith; Nicolas Moniaux; Surinder K Batra
Journal:  Mod Pathol       Date:  2006-07-28       Impact factor: 7.842

6.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

7.  Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.

Authors:  Siân Rizzo; Jenny M Hersey; Paul Mellor; Wei Dai; Alessandra Santos-Silva; Daniel Liber; Louisa Luk; Ian Titley; Craig P Carden; Garry Box; David L Hudson; Stanley B Kaye; Robert Brown
Journal:  Mol Cancer Ther       Date:  2011-01-07       Impact factor: 6.261

8.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

9.  Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.

Authors:  Isaac Kinde; Chetan Bettegowda; Yuxuan Wang; Jian Wu; Nishant Agrawal; Ie-Ming Shih; Robert Kurman; Fanny Dao; Douglas A Levine; Robert Giuntoli; Richard Roden; James R Eshleman; Jesus Paula Carvalho; Suely Kazue Nagahashi Marie; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Luis A Diaz
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

Review 10.  Big steps toward understanding dynein.

Authors:  Masahide Kikkawa
Journal:  J Cell Biol       Date:  2013-07-08       Impact factor: 10.539

View more
  34 in total

1.  TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target.

Authors:  Lin-Yu Chen; Rui-Lan Huang; Michael Wy Chan; Pearlly S Yan; Tien-Shuo Huang; Ren-Chin Wu; Yohan Suryo Rahmanto; Po-Hsuan Su; Yu-Chun Weng; Jian-Liang Chou; Tai-Kuang Chao; Yu-Chi Wang; Ie-Ming Shih; Hung-Cheng Lai
Journal:  J Pathol       Date:  2019-04-23       Impact factor: 7.996

Review 2.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

3.  The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer.

Authors:  Hiroshi Kobayashi; Kana Iwai; Emiko Niiro; Sachiko Morioka; Yuki Yamada; Kenji Ogawa; Naoki Kawahara
Journal:  Biomed Rep       Date:  2017-07-27

Review 4.  Serous tubal intraepithelial neoplasia: the concept and its application.

Authors:  Emily E K Meserve; Jan Brouwer; Christopher P Crum
Journal:  Mod Pathol       Date:  2017-01-20       Impact factor: 7.842

5.  PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.

Authors:  D A Modi; R D Tagare; S Karthikeyan; A Russo; M Dean; D A Davis; D D Lantvit; J E Burdette
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

6.  Stearoyl-CoA Desaturase 1 Protects Ovarian Cancer Cells from Ferroptotic Cell Death.

Authors:  Lia Tesfay; Bibbin T Paul; Anna Konstorum; Zhiyong Deng; Anderson O Cox; Jingyun Lee; Cristina M Furdui; Poornima Hegde; Frank M Torti; Suzy V Torti
Journal:  Cancer Res       Date:  2019-07-03       Impact factor: 12.701

Review 7.  Histone Methyltransferase EZH2: A Therapeutic Target for Ovarian Cancer.

Authors:  Bayley A Jones; Sooryanarayana Varambally; Rebecca C Arend
Journal:  Mol Cancer Ther       Date:  2018-03       Impact factor: 6.261

8.  EZH2 inhibition: a promising strategy to prevent cancer immune editing.

Authors:  Ning Kang; Mark Eccleston; Pier-Luc Clermont; Maryam Latarani; David Kingsley Male; Yuzhuo Wang; Francesco Crea
Journal:  Epigenomics       Date:  2020-09-17       Impact factor: 4.778

Review 9.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

Review 10.  FOXM1: A Multifunctional Oncoprotein and Emerging Therapeutic Target in Ovarian Cancer.

Authors:  Cassie Liu; Carter J Barger; Adam R Karpf
Journal:  Cancers (Basel)       Date:  2021-06-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.